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Physicians and Surgeons and New York Presbyterian Hospital, New York; 44Weill Cornell Medicine and and New York Presbyterian Hospital, New York; 45University
of Pennsylvania School of Medicine, Philadelphia, USA
*Correspondence to: Dr Anas Younes, Lymphoma Service, Memorial Sloan Kettering Cancer center, 1275 York Avenue, New York, New York, USA. Tel: þ001-212-639-7715;
E-mail: 10021.younesa@mskcc.org
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of
lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in
early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore,
with the advances in genome sequencing, new “basket” clinical trial designs have emerged that select patients based on the
presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria cur-
rently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tom-
ography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used
in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement
could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested
this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients en-
rolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assess-
ment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions.
Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients
receiving novel immune therapy and targeted agents that generate unique imaging situations.
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Introduction
The National Cancer Institute-sponsored international consen-
sus response criteria for lymphoma guidelines were published in
1999 and were subsequently revised in 2007 to incorporate assess-
ment of tumor metabolism by [18F]2-fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) [1–3]. More recently,
these criteria were further refined in the so-called Lugano
Classification, to incorporate a scoring system to enhance the re-
producibility of the interpretation and reporting of FDG-PET re-
sults, in addition to updating the recommended procedures for
staging evaluation [4]. These guidelines have facilitated the con-
duct and enhanced the analysis of clinical trials across different
institutions and geographic regions and provided the basis for an
objective comparison of the response assessments from different
treatment regimens. These guidelines are also frequently used by
regulatory agencies in their evaluation and approval processes of
new lymphoma drugs. However, these lymphoma response crite-
ria were mainly based on expert opinion and were not supported
by large-scale data analysis. As the number of novel antilymph-
oma targeted drugs that have entered clinical trials has substan-
tially increased; new clinical situations have emerged that were
not envisaged in the original criteria developed in the era of cyto-
toxic chemotherapy [5]. Some of these new agents have unique
mechanisms of action and have demonstrated excellent safety
profiles allowing extended dosing administration until disease
progression. However, the current definition of disease progres-
sion and partial remission depends on historically arbitrary crite-
ria that may not adequately reflect an individual patients’ clinical
benefit and often do not support clinical decisions to continue or
to stop therapy [6, 7]. Furthermore, many phase I/II clinical trials
of novel agents include patients with both solid tumors and
lymphoma, yet response assessment of these two disease catego-
ries is based on different criteria, resulting in different interpret-
ations [8]. Moreover, with recent advances in genome
sequencing studies and the identification of driver genetic alter-
ations across tumor types, novel clinical “basket” trial designs
have emerged for the treatment of patients with different tumors
that harbor specific genetic defects across different types of solid
tumors and lymphoma. To facilitate the evaluation of lymph-
omas in the era of precision medicine oncology trials, it is im-
portant to align lymphoma response criteria with the response
evaluation criteria in solid tumors (RECIST) [9].
The standard response criteria currently in use for lymphoma
are the Lugano Criteria which are based on PET or bidimensional
tumor measurements on computerized tomography (CT) for
non-FDG avid lymphomas, or when PET imaging is not available
[4]. These differ from the RECIST criteria used in solid tumors
which use unidimensional measurements [9]. In a pilot study, a
lymphoma-adapted RECIST was found to be simpler to use than
the 2007 lymphoma Response Criteria, while yielding similar re-
sponse rates [10, 11]. A second pilot study was conducted in 2013
by some of the authors of this manuscript using 175 cases from
four major academic centers also supported our hypothesis and
lead to the development of this projects (data not shown). With
this background, a group of leading international lymphoma ex-
perts from academic centers and pharmaceutical companies,
radiologists, and statisticians established a collaboration to har-
monize the lymphoma response criteria with RECIST, and to
evaluate the effect of using bidimensional or unidimensional
measurements on the assessment of best response for each sub-
ject, the proportion of subjects in each response category, and
progression-free survival (PFS). The new response evaluation cri-
teria in lymphoma (RECIL) was introduced and approved at the
International Workshop on non-Hodgkin lymphoma (iwNHL)
in San Diego on September 25, 2016.
Methods
Data were collected using a predefined purpose-designed tem-
plate, and the data were transcribed to the template from study-
specific case report forms. Measurements were collected from
previously measured lesions entered on study-specific case report
forms from 10 prospective multicenter trials (supplementary
Table S1, available at Annals of Oncology online). For each subject,
the target lesions (nodal and/or extranodal) were coded by the
number of lesions, from 1 to K, where K represents the number of
lesions for a given patient. The imaging dates were coded as 0 for
the initial scan (baseline) and as the number of days from the
baseline date for each follow-up scan. The length of the maximal
diameter and its perpendicular short diameter were provided for
lesions at each scan. Lesion measurement data which did not in-
clude lengths in both diameters, or which did not include the
date of measurement were excluded. Additionally, non-numeric
measurement values (such as “enlarged,” “improved,” “still ab-
normal but better”), measurements which were not present at
baseline, or measurements with 0 length in both dimensions at
baseline were also removed. Lesions in which a positive measure-
ment was recorded in the maximal diameter while a zero was re-
corded for its perpendicular were recoded assigning the
minimum perpendicular value in a given study in lieu of the zero
value (supplementary Figure S1, available at Annals of Oncology
online). Lesions not measured at visits post baseline were con-
sidered to have 0 length for both axes. Both Johnson and Johnson
data sources provided multiple reviewers for each lesion meas-
urement, of which one was selected at random for each patient
for analysis. Given the limited number of follow-up visits pro-
vided within the Children Oncology Group data, and the consid-
erably greater proportion of lesion measurements which were
missing or of poor quality, these data are excluded from analyses
involving response. In the three large industry-sponsored trials,
data from randomly selected patients were provided by the spon-
sor. Data from FDG-PET scan results were not provided, and
therefore were not part of this analysis.
For a subject let Xti denote the maximal diameter for lesion i at
scan time t and Yti the corresponding perpendicular dimension.
The uni-dimensional measurement is Xt1 þ    þ Xtk and the bi-
dimensional measurement is Xt1Yt1 þ    þ XtkYtk , where k is the
number of lesions for a given patient. The bidimensional meas-
urement is in square of the units of the unidimensional measure-
ment. Note that if every lesion changes by the same factor r in
both dimensions (that is X value at a follow-up visit is X(1þ r)
and likewise for Y) then the change will be r for the unidimen-
sional measurement and 2rþ r2 for the bidimensional measure-
ment. However a square-root transformation of the
bidimensional measurement will make the changes in the two
measurements equal. It is unrealistic to expect that a lesion that
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has a change in the longest diameter will have an identical change
in the perpendicular. For this reason, the goal of this analysis was
to evaluate how comparable the changes obtained using either
unidimensional or square-root transformed bidimensional
measurement are, and to what extent these changes effect re-
sponse designation and time to progression of disease (PD).
In order to evaluate the application of RECIST-like response
criteria to lymphoma, a comparison of the rules for response and
progression assessment was conducted. Under the current
Lugano response criteria for non-FDG avid lymphoma, a partial
response (PR) was defined as a 50% or greater reduction in the
area based on bidimensional measurements [4, 10]. When the le-
sion has a similar change in both dimensions, a 30% reduction in
each of the maximal and perpendicular axis results in nearly a
50% reduction in area, due to the fact that each diameter is then
70% of its original size with 0.7 * 0.7¼ 0.49, or 49% of the ori-
ginal area. Thus, we define the equivalent reduction in unidimen-
sional measurement as 30% (which is the threshold used by
RECIST) [12]. Likewise progression in lymphoma is defined as a
50% or greater in the area from nadir. Note that a 22.5% increase
in each of the maximal and perpendicular axis is needed for a
50% increase in area (1.225 * 1.225¼ 1.50, i.e. a 50% increase in
area). Thus, we define the equivalent increase in unidimensional
measurement as 22.5%, slightly higher than RECIST who uses a
threshold of 20% increase in diameter. With these modified
threshold, 30% for PR and 22.5% for progression, we computed:
the best response for each subject, the proportion of subjects in
each response category, the time to response and PFS.
Since depth of response is a post treatment time-varying cova-
riate we used a landmark analysis to determine the effect depth of
response had on PFS [13]. In the landmark analysis, a fixed time
point (landmark time) post baseline was selected and the depth
of response was defined as the best percent change observed be-
fore the landmark time. Patients who progressed or were lost to
follow-up before the landmark time are excluded from the ana-
lysis. PFS was then determined from the landmark time and the
effect of depth of response was assessed. We analyzed the associ-
ation by treating depth of response as a continuous variable and
estimating percentiles of PFS times using smoothing techniques
[14]. This method estimates the PFS percentile at a given depth of
response using a weighted Kaplan–Meier estimator using data
from patients whose depth of response is close to the target level.
The percentiles are presented as smooth function of depth of re-
sponse (percent change in tumor). As this analysis is qualitative
in nature, the results are presented descriptively [14]. The stron-
ger the association between depth of response and PFS, the
steeper we would expect the percentile curves to be and hence
shallow curves are indicative of minimal association.
Results
Tumor characteristics
A total of 47 828 unique measurements from 2983 individual pa-
tients enrolled on 10 multicenter clinical trials representing dif-
ferent lymphoma histologies, age groups (pediatrics versus
adult), line of therapy, and phase of study, were collected and
included in this analysis (supplementary Table S1, available at
Annals of Oncology online) [15–23]. The number of baseline tar-
get lesions that were measured in each study, number of visits for
imaging test used to perform tumor measurement, and the me-
dian and range of target lesion measurements for each clinical
trial at baseline, are shown in supplementary Table S2, available
at Annals of Oncology online.
Comparison between unidimensional and
bidimensional tumor measurements
Supplementary Figure S2A, available at Annals of Oncology on-
line, shows the scatterplot of the change in unidimensional (lon-
gest diameter) measurement plotted against the change in the
square-root of the bidimensional measurement plotted for all
subjects over all trial tumor-measurement visits. These same data
are also presented in a Bland–Altman plot [24] (supplementary
Figure S2B, available at Annals of Oncology online) with the lo-
cally weighted (LOESS) smooth fit [25]. As shown in supplemen-
tary Figure S3, available at Annals of Oncology online, a strong
correlation of these two measurements was observed at the indi-
vidual trial level, regardless of the number of lesions measured at
baseline for each patient, lymphoma histology, or line of therapy
(newly diagnosed versus previously treated). For the best re-
sponse category, we computed the maximum decrease in the lon-
gest diameter or area before progression. Additionally, any
patient who did not achieve a complete response (CR)/PR or PD
within 6 months was considered as having stable disease (SD).
Overall 94.5% [95% confidence interval (CI) 93.4% to 95.5%) of
patients remained in the same best response category by both
unidimensional and bidimensional methods. This relative change
is shown as a scatterplot (supplementary Figure S4A, available at
Annals of Oncology online) and waterfall plot (supplementary
Figure S4B, available at Annals of Oncology online) where the best
response by unidimensional and bidimensional methods is plot-
ted in red and blue, respectively, with purple representing where
the two methods overlap.
For calculation of PFS, progression was defined as the time that
the lesions first exhibited a50% increase in area or20% in-
crease (we also computed22.5% increase) in diameter from the
nadir value before that time-point. As shown in supplementary
Figure S5, available at Annals of Oncology online, the PFS curve
for the50% increase in area definition is quite similar to
the22.5% increase in diameter with the20% increase in
diameter curve coming in slightly below the other two. The asso-
ciation between PFS and criteria for progressive disease definition
was similar in patients treated with the first-line regimens and
those who were treated at disease relapse (supplementary Figure
S5, available at Annals of Oncology online)
Relationship between the depth of response and
PFS
The landmark analysis which assesses the association between
depth of response before the landmark time and PFS is shown in
supplementary Figure S6, available at Annals of Oncology online.
Since the previously untreated patients have different prognosis
than those who were previously treated, we grouped the trials
into the treated and untreated categories for this analysis.
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We chose the landmark time such that most of the patients in the
study have had the first follow-up scan by that time which in our case
was 6 months for the previously untreated patients and 3 months for
the previously treated ones. The top panels show the percentiles
when progressions were determined using unidimensional measure
and the bottom panels when using bidimensional measure. The per-
centiles were comparable across a broad range of depth of response.
PFS was comparable between the analysis conducted using either the
unidimensional or the bidimensional response measure.
Analysis of unidimensional measurement using the
short axis and long axis
In all the preceding analyses, the unidimensional measure for a pa-
tient was defined as the sum of the long axis of the target lesions in
a patient (up to the number of target lesions to be counted- see
supplementary Table S2, available at Annals of Oncology online).
The area was defined as the product of the long axis and the length
of the axis perpendicular to it, also called the short axis. We re-
peated the analysis by defining the unidimensional measure as the
sum of the short axes of the target lesions in a patient. The percent
change using the short-axis unidimensional measure is highly cor-
related with the area measure in the pooled data set and individual
trials (supplementary Table S3, available at Annals of Oncology on-
line) with the least strong correlation observed being 0.893 within
the PRIMA trial. The waterfall plot for the best response using the
short-axis uni-dimensional measure is similar to that of the long-
axis plot (supplementary Figure S7, available at Annals of Oncology
online). The high correlation of the short- and long-axis unidi-
mensional measures to the bidimensional area indicate that the
changes in the tumor appear to be consistently occurring propor-
tionally in both measured axes, and hence, either method of unidi-
mensional measurement adequately captures this change.
Number of target lesions required for response
assessment
We studied whether six target lesions should be included in re-
sponse evaluation as recommended by the Lugano Criteria, or a
smaller number could be used without loss of precision (as rec-
ommended by RECIST 1.1). To do so, we repeated the analysis
with 3, 4, 5, or 6 of the largest lesions at baseline among all the re-
corded lesions in a given subject. The best overall response based
on the N largest lesions is shown in supplementary Tables S4 and
S5, available at Annals of Oncology online. These data show that
using even as few as three target lesions allowed for 96.9% (95%
CI 96.0% to 97.6%) and 97.4% (96.6% to 98.0%) of the patients
to be assigned to the same response category as using six lesions,
by unidimensional and bidimensional criteria, respectively.
Additionally, in a comparison of best overall response category
by either unidimensional or bidimensional method, the best
overall response category remained identical for nearly 95% of all
patients regardless of whether all lesions, the largest 6, or the larg-
est 3 in terms of baseline diameter were used. Furthermore, the
use of three target lesions produced similar depth of response as
six target lesions (supplementary Figure S8, available at Annals of
Oncology online). The percent change in lesion measurements
over time was similar when up to 3, 4, 5, or 6 target lesions were
used (data not shown). Combined with the concordance of uni-
and bidimensional response categories, we can conclude that a
valid response designation can be achieved with a limited number
of lesions.
Consensus statement on staging and
response evaluation
Staging and assessment of baseline tumor burden
using unidimensional measurement of target
lesions
One of the most important factors that determine response to
therapy is related to the effect of treatment on the aggregate di-
mensions of all target lesions. The Lugano lymphoma response
criteria currently estimate the tumor burden by using the sum of
the products of the longest perpendicular diameters (SPD),
which is calculated by multiplying the two longest perpendicular
diameters for each target lesion. In contrast, RECIST 1.1 esti-
mates tumor burden using sum of diameters of target lesions
(longest diameter for non-nodal lesions and short axis for nodal
lesions) [9, 12]. Finally, the lymphoma Lugano Criteria for non-
FDG avid lymphoma calculate the baseline SPD for a maximum
of six target lesions and follow them over time to determine
tumor response. In contrast, RECIST 1.1 uses up to five target le-
sions. SPD measurements are performed by multiplying the lon-
gest perpendicular diameters for each of the target lesions. But as
lymph node shape and dimensions change with therapy, these
diameters can vary between observers, creating inconsistency
among investigator-reported and central review responses. The
use of one dimension, as required by RECIST, is easier to deter-
mine, and may enhance the reproducibility of response assess-
ment. In fact, a recent study demonstrated that nodal tumor
burden in follicular lymphoma strongly correlated with the lon-
gest diameter of the largest diseased lymph node [26].
Recommendation. Assessment of tumor burden in lymphoma
clinical trials can use the sum of longest diameters (SLD). In pa-
tients with disseminated disease, a maximum of three target le-
sions should be selected and used to estimate tumor response.
Target lesions should be selected from those with the largest size
that can be reproducibly measured and preferably representing
multiple sites and/organs. In most cases, lymph nodes can be con-
sidered target lesions if the lymph node longest diameter meas-
ures 15 mm. Similar to RECIST 1.1, a lymph node measuring
between 10 and 14 mm is considered abnormal but should not be
selected as a target lesion [12]. Lymph nodes measuring <10 mm
in diameter are considered normal [9]. In certain anatomical sites
(inguinal, axillary, and portocaval), normal lymph nodes may
exist in a narrow, elongated form, and such nodes should not be
selected as target lesions if alternatives are available. Extranodal
lesions are selected as target lesions if they have soft tissue compo-
nent, based on their size, and the ease of reproducibility of re-
peated measurements, with a minimum measurement of the
longest diameter of 15 mm. All other lesions should be identi-
fied as nontarget lesions and should be recorded at baseline, with-
out the need to measure them. Nontarget lesions should be
followed and reported as present, absent, or clear progression.
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For clinical trials, timing of pretreatment baseline scans should
be based on the clinical situations. For aggressive lymphoma,
such as diffuse large B-cell lymphoma, scans within 4 weeks
would be appropriate, but for indolent disease baseline scans may
be within longer window that should be defined in the study.
Whenever possible, the same imaging modality should be used at
baseline and subsequent visits. At the present time, CT scan imag-
ing, preferably with oral and intravenous contrasts remains the
gold standard for determining tumor measurements before, dur-
ing, and after completion of therapy. In certain situations where
minimization of exposure to ionizing radiation is desirable, or
where CT provides suboptimal assessment (such as primary bone
lymphoma), standard magnetic resonance imaging can be used
to determine baseline and subsequent tumor measurements.
FDG-PET should be included in the initial staging work up all
FDG-PET avid lymphomas [4, 27]. In certain cases, measure-
ments may be performed on the CT-component of a combined
PET/CT images, provided this is of adequate resolution.
In patients with newly diagnosed lymphoma, a bone marrow
biopsy should be performed at baseline to determine the stage of
disease. A baseline bone marrow biopsy is mandatory for previ-
ously untreated patients with indolent B-cell lymphoma, mantle
cell lymphoma, and T-cell lymphoma. Patients with diffuse large
B-cell lymphoma with a negative FDG-PET uptake in the bone
marrow, does not rule out bone marrow involvement, especially
discordant histology [28, 29]. However, a positive FDG-PET up-
take in the bone marrow may obviate the need for a bone marrow
biopsy [29]. Patients with Hodgkin lymphoma without FDG up-
take in the bone marrow or presence of B-symptoms do not need
a bone marrow biopsy at baseline, as bone marrow biopsy in this
situation is extremely unlikely to modify stage [30]. Bone marrow
biopsy may still be indicated to address special clinical scenarios,
such as evaluation for stem cell collection, and to rule out possible
myelodysplasia in patients with prolonged cytopenia.
Response assessment
Complete response. In the current Lugano Criteria, CR is defined
as complete normalization of FDG-PET uptake (Deauville score
of 1 to 3) or complete resolution of all target lesions for non-FDG
avid lymphoma or when PET cannot be performed [27]. PET re-
sults are also used to discriminate CR from a prior criterion
termed CR unconfirmed (CRu). End of treatment PET usually
refers to predefined number of chemotherapy-based regimens
that are typically administered for six to eight cycles. Several new
agents have been reported to modulate tumor metabolism, glu-
cose uptake, and inflammation in the tumor microenvironment,
and therefore may potentially increase the false-positive or false-
negative FDG-PET results [31].
Recommendation: CR is defined as a complete resolution of all
target lesions by CT scans with complete normalization of FDG-
PET uptake in all areas (Deauville score of 1–3), and bone mar-
row biopsy negativity (if it was positive or unknown at baseline).
If pretreatment PET scan was negative, lymph nodes that meas-
ured 15 mm in the long axis should regress to < 10 mm. CR is
also defined as achievement of a partial remission by CT scan cri-
teria (reduction in sum of longest diameters by CT imaging by
>30%) with normalization (Deauville score 1–3) of FDG-PET
activity in FDG-avid lymphoma (Table 1). Because many novel
Table 1. RECIL 2017: Response categories based on assessment of target lesions
% Change in sum of diameters of target lesions from nadir




ance of all target le-
sions and all nodes
with long axis
<10mm.
• 30% decrease in the
sum of longest diam-
eters of target lesions
(PR) with normaliza-
tion of FDG-PET
30% decrease in the
sum of longest diam-
eters of target lesions
but not a CR
10% decrease in the
sum of longest diam-
eters of target lesions
but not a PR (<30%)
<10% decrease
or 20% increase in
the sum of longest
diameters of target
lesions
• >20% increase in the
sum of longest diam-
eters of target lesions
• For small lymph
nodes measuring
<15 mm post therapy,
a minimum absolute
increase of 5 mm and
the long diameter
should exceed 15 mm
• Appearance of a new
lesion
FDG-PET Normalization of FDG-







Not involved Any Any Any Any
New lesions No No No No Yes or No
CR, complete response; CT, computerized tomography; FDG-PET, [18F]2-fluoro-2-deoxy-D-glucose; MR, minor response; PD, progression of disease; PR,
partial response; SD, stable disease.
aA provisional category.
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targeted agents may alter glucose uptake and/or metabolism, nor-
malizing of FDG-PET imaging alone is not sufficient by itself to
determine CR status unless accompanied with a significant
(>30%) decrease in the sum of diameters. Accordingly, a reduc-
tion in the sum of diameters by 30% with normalization of
FDG-PET uptake should not be considered a CR unless docu-
mented by a negative tissue biopsy. PET-based CRs should be
identified by specific designation on waterfall plots (Figure 1).
In cases where pretreatment baseline tumor burden is low,
with only a few lesions measuring around 2 cm in longest diam-
eter, treatment effect may shrink the long axis of a target lymph
node to a normal values of <10 mm. However, even though the
lymph node is now within normal size range, consistent with CR,
the percentage of diameter reduction may be <30% (less than a
PR). In these cases, a normalized diameter of “0, or resolved”
(Table 2, method 2) should be used to calculate the sum of diam-
eters, and therefore ensuring accurate response designation.
Accordingly, a “normalized” calculation should be used when
creating a waterfall plot.
Partial response. In the current Lugano lymphoma Response
Criteria, PR is defined as a decrease in the SPD of target lesions
by 50%, with no increase in the size of any lesion, and no ap-
pearance of new lesions. Typically, one or more lesions are also
PET avid. A scenario is often encountered whereby the size of one
or more lesions is increased by 50%, even though the overall
SPD is decreased by more than 50% from baseline, This “mixed
response” is designated as PD in the current Lugano Criteria [4].
In contrast, RECIST designation of a response is based on the
overall changes in the sum of diameters, irrespective of a mixed
response. Because many phase-I studies include patients with
solid tumors and lymphoma, the discrepancy between the
Lugano Criteria and RECIST creates regulatory concerns of how
these responses should be reported.
Recommendation: Consistent with RECIST, PR is defined as a
reduction of the sum of longest diameters of target lesions by
30%, but without meeting the definition of CR described above
(Table 1; Figure 1). If one or more target lesions grew in size but
the sum of the diameters remains30% of the baseline measure-
ment, and no new lesions appear, the response should be desig-
nated PR. This revised definition will eliminate the false
interpretation of disease progression due to treatment-related in-



















Figure 1. Treatment outcome by response category using a waterfall plot, Responses are color coded based on the cutoffs shown in Table
1. Red, progression of disease; pink, stable disease; orange, minor response; blue, partial response; dark green, complete response. Light
green bars denote complete response based on integrating PET results. The horizontal dotted lines show the boundaries for partial response,
minor response, stable disease, and progression of disease (Table 1).
Table 2. Calculating sum of diameters to include small responsive lymph nodes
Target lesions Baseline measurement
(long axis; cm)
Nadir actual
measurement (cm) method 1
Nadir normalized
measurement (cm) method 2
Lesion 1 1.6 0.9 0 (resolved)
Lesion 2 1.7 1.4 1.4
Lesion 3 2 1.8 1.8
Sum of diameters 5.3 4.1 3.2
% change from baseline N/a 23 40
Response designation N/A Minor response Partial response (or CR if PET is negative)
CR, complete response; PET, positron emission tomography.
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agents (see “Special Cases” section) and will eliminate early ter-
mination of potentially beneficial therapy in an otherwise
noncurable clinical setting.
Minor response. Neither the Lugano Criteria nor RECIST include
the designation of minor response (MR). In the Lugano Criteria,
the designation of SD includes changes in the SPD, ranging be-
tween -49% andþ50% (for RECIST, the range is29% toþ20%
of the sum of diameters). Lumping such a wide range of changes
in tumor measurements in one response category is clinically un-
informative, as different changes may require different thera-
peutic interventions. Furthermore, with the use of modern
imaging methods, precise changes in tumor measurements are
frequently reported in waterfall plots. Many new agents have
been shown to reduce tumor measurements relative to baseline,
but not fulfilling the criteria for a PR. In patients who did not
achieve a CR, the depth of response did not correlate with PFS
(see supplementary Methods and Results available at Annals of
Oncology online). This is not surprising, since the definition of
PR was based on a historically arbitrary cutoff in tumor reduc-
tion. In fact, recent analysis of several phase II studies of single
agents in relapsed lymphoma suggested that patients with PR had
a similar PFS compared with those who had some tumor reduc-
tion that was below the cutoff of a PR [32–34].
Recommendations: A new provisional category of MR should
be included in the response assessment. Using single diameter
long-axis measurements, MR is defined as a reduction in the SLD
of target lesions by 10% but <30%, without the appearance of
any new lesions, and irrespective of PET scan results (Table 1;
Figure 1). This cutoff was conservatively chosen, to eliminate a
potential margin of measurement error, and therefore, it is con-
sidered a provisional category. A mixed response will be called a
MR, as long as the sum of longest diameters is consistent with a
MR.
Stable disease. In many cases of chronically administered new
agents, including immune therapies, the best response to treat-
ment may only be achieved after prolonged administration of
therapy [35, 36]. Accordingly, an initial designation of SD should
not be a basis for premature termination of therapy, especially if
treatment is well tolerated, as the quality of response may im-
prove with time to become MR, PR, or CR. In addition, the pa-
tient may derive benefit from a given therapy even if a response is
not achieved.
Recommendation: SD is defined as changes in the SLD of tar-
geted lesions ranging between reduction of <10% to an increase
by20% without the appearance of a new lesion, and irrespective
of PET results (Table 1; Figure 1). Mixed responses will be called
SD as long they fulfill the above criteria. This definition is used in
lymphoma-specific clinical trials when an MR is included in the
study aims. In clinical trials that include both lymphoma and solid
tumors, whereas RECIST does not include a MR category, the def-
inition of SD should remain similar to RECIST (29% toþ20%)
Progression of disease. The definition of PD should be consistent
with loss of benefit of therapy, requiring stopping or changing
treatment. The current Lugano Criteria defines PD as having any
of the following categories: (i) appearance of any new lesion of
>1.5 cm in longest diameter, (ii) an increase of at least 50% from
nadir in the SPD of any previously involved lymph nodes, (iii) at
least a 50% increase in the longest diameter of any single previ-
ously identified node >1 cm in its long axis. This definition is in
conflict with clinical practice as it calls for stopping or changing
therapy when a single lymph node increases in size from 1.0 to
1.6 cm, even though the overall SPD may have shown significant
reduction. Moreover, as several novel agents have been shown to
induce a local immune response or a “flare,” an increase in lymph
node sizes temporally corresponding with the initial cycles of ad-
ministration of therapy may not necessarily be due to progression
of the disease [36, 37].
Recommendations: Consistent with RECIST 1.1, and using a
unidimensional tumor measurement, PD after initiating a new
therapy is defined as an increase in the sum of longest diameters
of target lesions by >20%, and/or appearance of a new lesion
(lymph node or a soft tissue mass10 mm of the longest diam-
eter), irrespective of FDG-PET results (Table 1). Whenever pos-
sible, questionable small FDG-PET avid lesions should be
confirmed by a histologic or cytologic analysis. Appearance of a
new FDG-PET avid lesion that is smaller than the above thresh-
olds should be closely monitored, and whenever possible, a bi-
opsy should be performed to determine its nature. An increase in
the size of previously involved small lymph nodes by>20% while
other lesions are decreasing, especially at the beginning of treat-
ment with investigational agents, may represent a tumor flare
and should not be designated a PD, unless there is continued in-
crease in size on subsequent imaging studies. Patients should be
allowed to remain on trial at investigators and patient discretion
until the response or lack thereof is clarified on subsequent
imaging.
Progression after an initial response. The current Lugano re-
sponse criteria use nadir tumor measurements as the new base-
line for defining PD, and therefore, even a small regrowth of one
or more lymph nodes is defined as PD, requiring stopping or
changing therapy. This definition may paradoxically result in
shorter PFS times in patients who achieve the best response.
Unlike patients with relapsed and refractory solid tumors, pa-
tients with lymphoma frequently achieve CRs and very good PRs,
where the nadir tumor measurement can be very low compared
with baseline. To avoid premature termination of therapy due to
minor fluctuations or a small increase in tumor measurements
from the nadir, especially in patients with no available curative
options, patients may be allowed to continue receiving therapy
beyond the strict definition of PD as long as (i) the patient does
not have prohibitive toxicity and (ii) the patient remains free
from significant disease-related symptoms. By doing so, the time
for changing therapy or discontinuation of therapy can be a more
useful measure of determining treatment success compared with
PFS. However, if used, this end point should be prospectively and
clearly stated in the objectives of clinical trials.
Recommendation: After an initial response, and in the absence
of appearance of new lesions, PD is defined as an increase of the
nadir sum of diameters by >20%. Consistent with RECIST 1.1,
patients who achieve a CR (normalization of all lymph node
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measurements and disappearance of extranodal lesions), at least
one previously involved lymph node should increase in size to
measure15 mm in the long diameter, with a minimum absolute
increase of at least 5 mm from nadir [9, 12] Accordingly, an in-
crease in a lymph node longest diameter from 8 to 13 mm is not
considered a PD, even though there is 38% increase in the meas-
urement, since the lesion did not exceed 15 mm. Similarly, a
change from 12 to 16 mm does not qualify as a PD even though
the new measurement exceeds 15 mm, since the absolute increase
was <5 mm. In the absence of alternative treatment options,
lymphoma-related symptoms, and no new lesions, treatment
may continue beyond PD with periodic follow up imaging stud-
ies, to prolong patient’s clinical benefit. Such a plan, which
should be prospectively included in the study design and should
not redefine of PFS, may allow capturing data to calculate time to
next therapy or time to discontinuation of therapy. If used in
clinical trials, this aim should be prospectively described in the
study design and in the consent form.
Time to progression, PFS, event-free survival, and
overall survival
Time to progression is defined as the time from study entry until
disease progression. PFS is defined as the time from start of study
entry until disease progression or death. Event-free survival
(EFS) should be reserved to define specific events that are in-
tended to be prevented or delayed by therapy. Events are
prespecified for each study and may include implementing a
change of therapy, disease progression, disease relapse, second
malignant neoplasms, and death of any cause. EFS is measured
from the time from study entry to the event. Overall survival is
defined as the time from study entry or initial diagnosis until
death from any cause.
Response assessment in patients receiving
immune modulating agents, including immune
checkpoint inhibitors
Immunomodulating agents, such as lenalidomide, and new
immunotherapies, such as immune check point inhibitors, in
addition to cell therapy with chimeric antigen receptor engin-
eered T cells can be associated with a “pseudo-progression”
that may be related to recruitment of immune cells to disease site
[36, 38–46]. After initial recruitment of activated T cells, the
tumor lesion may transiently increase in size before shrinking. To
avoid premature termination of such therapies, an immune-
related response criteria were developed which required confirm-
ation of PD on two consecutive scans at least 4 weeks apart, and
inclusion of new lesion measurements to the total tumor burden
[47–50]. These criteria are distinct from RECIST and the Lugano
Criteria, which define PD at tumor burden increase above the
specified threshold (20% for RECIST and 50% for Lugano
Criteria) or at the appearance of new lesions, without the need
for confirmation on subsequent imaging. When serial imaging
studies confirms that the prior increase in tumor measurements
was related to an early manifestation of disease progression rather
than a tumor flare, the time of progression should be back-dated
to the initial scans that documented PD.
Response assessment in patients receiving agents
that mobilize lymphoma cells from lymph nodes
and bone marrow into the blood
Some agents can inhibit adhesion mechanisms in tumor cells
causing redistribution of tumor cells from lymph nodes and/or
bone marrow into the blood. Thus, while lymph node size de-
crease in response to therapy, the tumor cell count increases in
the blood, creating another form of “pseudo-progression”. With
continued therapy, blood lymphocytosis decrease as tumor cells
start to die. This phenomenon has been observed with BTK and
PI3K inhibitors [51–58]. Accordingly, increased lymphocytosis
in the setting of a decrease in lymph node measurement is not
considered PD, and response designation should depend on
lymph nodes and extra-nodal disease measurement.
Lymphocytosis can be included as annotation. For example, PR
with increased lymphocytosis.
Appearance of a new extranodal lesion
With the use of PET imaging, a new small PET avid lesion may
appear during or after therapy, but there are no guidelines on
how to interpret such lesions to define PD. Ideally, such lesions
should be biopsied where clinically feasible to clarify their nature,
but frequently they are too small to biopsy. Eventually, with ob-
servation, the nature of such lesions is clarified. Pulmonary or
skin infection and arthritis may result in false positive PET activ-
ity and may be confused with an early progression. A retrospect-
ive approach may not be appropriate as it creates confusions as
patients’ records and source documents will require corrections.
On the other hand, a delayed declaration of PD may also create
concerns of data integrity for regulatory oversight of clinical tri-
als, especially when a drug is undergoing an approval process by a
regulatory authority. Therefore, a uniform and transparent ap-
proach should be implemented.
Recommendation. A minimum of 1 cm in largest diameter of new
extra-nodal lesions is required to assign PD directly. New smaller
but suspicious lesion should be designated as equivocal, and if
later confirmed (by CT or biopsy) as being due to lymphoma, the
documented date of progression should be the date of when it
was first identified as equivocal
Integrating target and nontarget lesions in the
response assessment
In case of disseminated disease, the status of non-target lesions
should be taken into account before formulating the final re-
sponse status. A recommended approach is shown in Table 3.
Measurement of splitting lesions
Frequently, effective therapy may convert a large confluent mass
to several smaller constituent lymph nodes (Figure 2). In this
case, and consistent with RECIST, the measurement of each
lymph node should be carried out and entered in the calculation
of sum of diameters. However, to avoid an overall increase in the
number of target lesions, sub-designations of A, B, C, etc. for any
target lesion that has undergone splitting should be created.
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Spleen measurement
Spleen size may vary considerably in size and shape in healthy in-
dividuals and typically is not selected as a target lesion. In the
Lugano Criteria, splenomegaly is defined as greater than 13 cm in
“vertical length.” This definition might be confusing for some
radiologists since it does not specify the plane that is commonly
used by radiologist. To clarify this recommendation, vertical
length measurement should be carried out in the coronal image
as shown in Figure 3. Alternatively, the spleen vertical length can
be calculated by multiplying the number of spleen slices in trans-
verse CT views by the thickness of each slice, or by measuring
splenic coronal diameter on a PET maximum intensity projection
image
Reporting response results in waterfall plots
Actual percentage changes in sum of diameters should be
reported, with special consideration of the definition of CR
(Figure 1). If PET status is used to designate a CR (i.e. PR with
negative PET), then these patients should be identified by a separ-
ate color of the bars, or by an asterisk in a waterfall plot. In calcu-
lating sum of diameters, target lymph node lesions that decrease
in size to <1.0 cm and became PET negative, may be recorded as
resolved or “0” (Table 2). Splitting lesions should be included in
the sum of diameters measurement when reporting results in
waterfall plots.
Frequency of response assessment
Several investigational agents have been shown to be safely
administered for a prolonged period of time requiring several
repeated imaging studies, raising concerns about a potential
increased risk of radiation exposure. While an accurate assess-
ment of PFS is critical during the first 6 months of initiating
therapy with investigational agents, less frequent imaging
assessments are reasonable with ongoing prolonged treatment.
A uniform incorporation of surveillance intervals in clinical
studies will be important to allow comparison of PFS response
assessment across different trials [59].
Recommendation. In phase I/II clinical trials in previously
treated patients, it is recommended that response assessment be
carried out every 2–3 months during the first year of therapy. In
the absence of new symptoms or clinical concerns, subsequent
imaging studies can be carried out every 3–4 months during the
second year, and every 6 months thereafter, for the duration
specified in the clinical trial. Imaging assessment may be carried
out less frequently during and after therapy of newly diagnosed
patients, and in the settings of randomized phase III studies.
In some countries, local health authorities and ethics commit-
tees may demand longer imaging intervals for response
assessments.
Conclusions and future directions
The proposed new RECIL criteria are aligned with RECIST, and
are applicable for both adult and pediatric patients with lymph-
oma (Table 4). While most of our recommendations are sup-
ported by large data analysis, some remain based on consensus
recommendations, including the requirement for tissue biopsy to
confirm CR of PET negative disease in the setting of minor reduc-
tion in tumor measurement, the proposed minimum increase in
the size of lymph nodes to qualify as PD, the optimal method of
evaluating splenomegaly, the optimal intervals of imaging studies
to monitor response to therapy, and the optimal staging catego-
ries that may better predict treatment outcome. Furthermore, the
proposed new category of MR will need to be prospectively vali-
dated to determine its usefulness in guiding clinical practice and
clinical research.
With >60 lymphoma histologic subtypes, and many different
clinical presentations related to organ site involvement and bulk
Target lesion 1 Target lesion 1 (A, B and C)
Figure 2. Measurement of a splitting lesion in response to therapy.
Table 3. Response designation incorporating best response of target
lesions (Table 1) and nontarget lesions
Target lesion Nontarget lesion New lesion Response
designation
CR CR No CR
CR PR, MR, or SD No PRa
CR UE No UE
PR UE No UE
PR CR No PR
PR PR, MR, or SD No PR
MR UE No UE
MR CR No MR
MR PR, MR, or SD No MR
SD UE No UE
SD CR, PR, or MR No SD
SD SD No SD
PD Any Yes/no PD
Any PD Yes/no PD
Any Any Yes PD
CR No No CR
PR No No PR
MR No No MR
SD No No SD
CR, complete response; MR, minor response; PD, progression of disease;
PR, partial response; SD, stable disease; UE, unevaluable.
aAs in Table 6, computerized tomography scan-based PR with com-
plete normalization of [18F]2-fluoro-2-deoxy-D-glucose positron emis-
sion tomography activity is considered CR.
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of the disease, it is impossible for a response criteria to cover all
possible scenarios. Accordingly, it is possible that certain clinical
scenarios may require a slight modification of the proposed
RECIL 2017. For example, although our proposed criteria is ap-
plicable for bulky and non-bulky target lesions, in certain clinical
presentations such as primary mediastinal diffuse large B-cell
lymphoma, and classical Hodgkin lymphoma with bulky medias-
tinal disease, the definition of CR may require modification. In
some patients with these two lymphoma types, a CR is typically
defined by a PET negative status at the end of therapy, regardless
of the percentage of tumor size reduction by CT scan. However,
the core principle of the RECIL 2017, including using the sum of
longest diameters and the inclusion of up to three target lesions
should remain the same.
Future directions should evaluate the role of molecular depth
of response (minimal residual disease and circulating DNA) in
predicting treatment outcome, and to guide future studies aimed
at evaluating shorter duration of therapy. Our new RECIL
Figure 3. Recommendation for measuring spleen long diameter. (A) Coronal view of a computerized tomography (CT) scan image,
(B) maximum intensity projection image of a positron emission tomography/CT.
Table 4. Comparison between RECIST 1.1, Lugano lymphoma classification, and RECIL 2017
RECIST 1.1 Lugano RECIL 2017
Number of target lesions Up to 5 Up to 6 Up to 3
Measurement method Uni-dimensional: long diameter of








May be considered to confirm CR
and/or to declare PD based on
detecting new lesions
Yes Yes
Minor response No No Yes, reduction in sum of long diam-
eters between 10% and <30%
Stable disease 29% toþ 20% 50% toþ 50% decrease <10% to increase 20%
PD Increase in sum of diameters by
20%
Increase in the sum of products of
perpendicular diameters
by> 50%, or any single lesion
by> 50%
Increase in sum of the longest
diameters by 20%. For relapse
from CR, at least one lesion
should measure 2 cm in the long
axis with or without PET activity
CR, complete response; PD, progression of disease; PET, positron emission tomography.
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proposal should also be evaluated by the RECIST investigators to
consider further harmonization of the criteria, with a special at-
tention to the measurement of the long axis of lymph nodes, opti-
mal number of target lesions, and introduction of MR category.
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